Mark A. Socinski
Impact in
- Oncology top 0.05%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 318
- Lung Cancer Diagnosis and Treatment 113
- Oncology 277
- Lung Cancer Research Studies 130
- Colorectal Cancer Treatments and Studies 69
- Cancer Immunotherapy and Biomarkers 59
- Cancer Treatment and Pharmacology 39
- Co-authors
- Thomas E. Stinchcombe (70 shared papers)Martin Reck (23 shared papers)Robert M. Jotte (34 shared papers)Liza C. Villaruz (28 shared papers)Federico Cappuzzo (26 shared papers)Fabrice Barlési (20 shared papers)Delvys Rodríguez‐Abreu (13 shared papers)Daniil Stroyakovskiy (12 shared papers)
- Journals
- Journal of Clinical Oncology (143 papers)Journal of Thoracic Oncology (70 papers)Annals of Oncology (41 papers)Lung Cancer (34 papers)Clinical Lung Cancer (29 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Mark A. Socinski
509 papers receiving 22.6k citations
Mark A. Socinski's Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 11.7k
- Pulmonary and Respiratory Medicine 11.4k
- Cancer Research 2.3k
- Immunology 1.5k
- Hepatology 443
Countries citing papers authored by Mark A. Socinski
This map shows the geographic impact of Mark A. Socinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Socinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Socinski more than expected).
Fields of papers citing papers by Mark A. Socinski
This network shows the impact of papers produced by Mark A. Socinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Socinski. The network helps show where Mark A. Socinski may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark A. Socinski, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 522 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Hit paper breakdown → | 2018 | 2714 |
| 2 | Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Hit paper breakdown → | 2008 | 1027 |
| 3 | Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial Hit paper breakdown → | 2012 | 613 |
| 4 | Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression Hit paper breakdown → | 1988 | 580 |
| 5 | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial Hit paper breakdown → | 2015 | 476 |
| 6 | Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Hit paper breakdown → | 2020 | 422 |
| 7 | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial Hit paper breakdown → | 2015 | 355 |
| 8 | 2016 | 343 | |
| 9 | IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC Hit paper breakdown → | 2021 | 340 |
| 10 | Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy Hit paper breakdown → | 2017 | 315 |
| 11 | Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial Hit paper breakdown → | 2020 | 301 |
| 12 | 2013 | 289 | |
| 13 | 2008 | 284 | |
| 14 | 2004 | 283 | |
| 15 | 2002 | 283 | |
| 16 | 2014 | 242 | |
| 17 | 2003 | 239 | |
| 18 | 2006 | 224 | |
| 19 | 2012 | 209 | |
| 20 | 2014 | 205 |
About Mark A. Socinski
Mark A. Socinski is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 522 papers that have together received 23.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (318 papers), Lung Cancer Research Studies (130 papers), Lung Cancer Diagnosis and Treatment (113 papers), Colorectal Cancer Treatments and Studies (69 papers), Cancer Immunotherapy and Biomarkers (59 papers), Cancer Genomics and Diagnostics (52 papers), Cancer Treatment and Pharmacology (39 papers) and Hepatocellular Carcinoma Treatment and Prognosis (24 papers). The work is most often cited by research in Oncology (11.7k citations), Pulmonary and Respiratory Medicine (11.4k citations), Cancer Research (2.3k citations), Immunology (1.5k citations) and Hepatology (443 citations). Mark A. Socinski has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Thomas E. Stinchcombe, Martin Reck, Robert M. Jotte, Liza C. Villaruz, Federico Cappuzzo, Fabrice Barlési, Delvys Rodríguez‐Abreu, Daniil Stroyakovskiy, Francesco Orlandi and Julian Rosenman. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.